SARS virus articles from across Nature Portfolio

Evolution of SARS-CoV-2 and emergence of other sarbecoviruses are of potential concern. Here, the authors designed a trivalent spike-protein-nanoparticle vaccine that elicits neutralizing antibodies and protects female hamsters against challenges with SARS-CoV-2-like and SARS-CoV-1-like coronaviruses.

Most current anti-coronavirus nanoparticle vaccines target epitopes within the RBD. Here, the authors developed nanoparticles displaying an array of spike fusion proteins derived from various coronaviruses and show that immunizing mice with these vaccines elicits broad and potent cross-reactive antibodies.

Analysis of data from the US Department of Veterans Affairs showed that 2 years after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, risk for most postacute sequelae remained elevated in people who were hospitalized with COVID-19 but was attenuated in nonhospitalized individuals.

In this study, Lee et al. analyse the structure and receptor-binding features of the spike glycoprotein from a clade 3 sarbecovirus to examine the risk of spillover from bats to humans.